Drug Profile
Exendin 3
Latest Information Update: 10 Jul 2002
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer Amylin Pharmaceuticals; Nonindustrial source
- Class Amino acids; Peptides
- Mechanism of Action Peptide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 10 Jul 2002 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route)
- 04 Aug 1998 No-Development-Reported for Diabetes mellitus in USA (Unknown route)
- 04 Nov 1996 New profile